This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Boston Scientific (BSX) and Conmed (CNMD) have performed compared to their sector so far this year.
The Zacks Analyst Blog Highlights Amazon.com, Boeing, Regeneron, Boston Scientific and Waste Management
by Zacks Equity Research
Amazon.com, Boeing, Regeneron, Boston Scientific and Waste Management are part of the Zacks top Analyst Blog.
Boston Scientific (BSX) Set to Acquire Relievant Medsystems
by Zacks Equity Research
Boston Scientific's (BSX) new M&A deal is likely to broaden the Neuromodulation business portfolio.
Top Stock Reports for Amazon.com, Boeing, Regeneron & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), The Boeing Company (BA) and Regeneron Pharmaceuticals, Inc. (REGN).
PBH vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBH vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific (BSX) WATCHMAN FLX Pro Gets FDA Approval
by Zacks Equity Research
Boston Scientific's (BSX) latest device features a polymer coating, visualization markers and a broader size matrix to treat a wider range of patients.
Here's Why You Should Retain Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) on growth in the legacy business and upbeat guidance.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Boston Scientific's (BSX) FARAPULSE System Study Data Positive
by Zacks Equity Research
Boston Scientific's (BSX) FARAPULSE PFA System's performance in the trial is an encouraging sign of the potential utilization of the device in the United States.
If You Invested $1000 in Boston Scientific a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
PBH vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PBH vs. BSX: Which Stock Is the Better Value Option?
Company News for Aug 29, 2023
by Zacks Equity Research
Companies in The News Are: MMM,JD,RPT,KIM,BSX
Top Analyst Reports for Procter & Gamble, AbbVie & Walt Disney
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), AbbVie Inc. (ABBV) and The Walt Disney Company (DIS).
Boston Scientific (BSX) Expands Globally Amid FX Concerns
by Zacks Equity Research
Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.
Boston Scientific's (BSX) POLARx System Gets FDA Approval
by Zacks Equity Research
Boston Scientific's (BSX) POLARx enables doctors to expand and modify the new POLARx catheter to match a patient's unique anatomy during an ablation treatment.
BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited Q3 sales.
Acadia Healthcare (ACHC) Q2 Earnings Beat on Higher Admissions
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q2 results indicate improved patient days and revenue per patient day. Management expects 2023 adjusted EPS of $3.25-$3.50.
Molina (MOH) Q2 Earnings Beat on High Premiums, '23 View Raised
by Zacks Equity Research
Molina Healthcare's (MOH) second-quarter results are aided by increased membership, and Medicaid and Medicare strength.
Boston Scientific (BSX) Q2 Earnings Beat, Margins Improve
by Zacks Equity Research
Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the second quarter.
Boston Scientific (BSX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Boston Scientific (BSX) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Boston Scientific (BSX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 8.16% and 2.88%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q2 Earnings on Jul 27: BSX, LH & IART
by Urmimala Biswas
Medical Device companies' second-quarter results are likely to reflect a year-over-year decline. Let's see how BSX, LH and IART fare this time.
5 Must-Buy Stocks Ahead of Q2 Earnings Tomorrow
by Nalak Das
We have narrowed our search to five stocks that are set to declare second-quarter earnings results on Jul 27, before market open. These are: HON, BSX, AOS, SPGI, ATHM.
Will Growing Customer Base Aid Centene (CNC) in Q2 Earnings?
by Zacks Equity Research
Centene's (CNC) Q2 results are likely to reflect growing Medicaid and Marketplace membership, coupled with an improved HBR, partly offset by escalating medical expenses.
Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.